ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1040 participants.

Also called NCT05672836

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,040 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05672836
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05672836. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
Acronym
ENAVO-TAVR
Condition
Aortic Valve Stenosis
Condition
Heart Failure
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Standard-of-Care
Lead sponsor
Duk-Woo Park, MD (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct05672836
Content hash
26fc113f7dc346676098e8767a81515d25695900eb5340e4aaefa6bb9a2cae85